Prosztatarák: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• PSMA 273
• AR 16
• TP53 2
• PARP 13
• PTEN 4
• AKT 1
• BRCA2 7
• BRCA1 9
• STAT3 0
• PI3K 2
• PD-L1 6
• mTOR 1
• PD-1 13
• EZH2 7
• MYC 1
• B7-H3 8
• EGFR 2
• CTNNB1 1
• JNK 0
• ERK 0
• HIF-1 0
• VEGF 2
• BCL-2 0
• MAPK 0
• AMPK 0
• CDK4/6 4
• HER2 6
• NRF2 0
• FAK 0
• PPAR 0
• YAP 0
• IL-6 0
• STING 0
• COX-2 0
• CTLA-4 0
• DLL3 6
• GLP-1 1
• GPX4 0
• HSP90 0
• ATM 1
• HDAC 0
• IL-15 4
• METTL3 1
• BRD4 0
• HER3 2
• JAK 1
• CXCR4 0
• TROP2 3
• CD47 1
• IGF1R 0
• IL-1 0
• MET 1
• PALB2 4
• RB1 0
• TNF 0
• APOE 0
• FGFR 1
• KRAS 0
• MDM2 0
• MEK 0

3735 intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · P01

  Understanding and targeting treatment-associated lineage plasticity in cancer

  Columbia University Health Sciences· New York, Egyesült Államok· 2 729 322 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NCI · R01

  The role of GRK3-HDAC2 epigenetic pathway in neuroendocrine prostate cancer and immune evasion

  Methodist Hospital Research Institute· Houston, Egyesült Államok· 514 864 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NCI · R01

  Elucidating upstream and downstream NUAK2 mechanisms in neuroendocrine prostate cancer

  Augusta University· Augusta, Egyesült Államok· 518 589 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NCI · R56

  The role of AKT isoform-preferred substrates in prostate cancer aggressiveness

  Roswell Park Cancer Institute Corp· Buffalo, Egyesült Államok· 130 125 USD awarded in fiscal year 2026· until 2027. aug.

• NIH NCI · R01

  Analysis of epithelial heterogeneity and plasticity in prostate development and cancer

  Columbia University Health Sciences· New York, Egyesült Államok· 613 866 USD awarded in fiscal year 2026· until 2031. júl.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Targeting stress signaling pathways to enhance prostate cancer immunotherapy (IMMSTRESS)

  Deutsches Krebsforschungszentrum Heidelberg· Heidelberg, Németország· EU contribution 202 125 EUR· until 2029. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Circulating Tumor Cell-informed RADioresponse Assessment from heme-axis signatuRes (CTC-RADAR)

  Koc University· Istanbul, Törökország· EU contribution 398 612 EUR· until 2029. dec.· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  EXPLORING THE MECHANISM OF METASTASIS/DEVELOPMENT OF NEW TESTS TO ENROLL CIRCULATING TUMOR CELLS (CTCs) INTO CLINICAL PRACTICE (CTC4CLINIC)

  Panepistimio Patron· Rio Patras, Görögország· EU contribution 796 590 EUR· until 2030. dec.· 7 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Exploitation of bioorthogonal click-to-release chemistry for precision cancer therapy (click-to-cure)

  Kobenhavns Universitet· Kobenhavn, Dánia· EU contribution 247 553 EUR· until 2028. dec.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  A Proteoform-Resolved Lateral Flow Immunoassay with Antibody Mimics and Engineered Release for Precise Prostate Cancer Diagnosis (PRIME)

  The Chancellor, Masters and Scholars of the University of Oxford· Oxford, Egyesült Királyság· EU contribution 260 348 EUR· until 2028. szept.

10 of 74 running projects, newest first. Listed amounts together: 30,6 M USD + 116,1 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics

  NCT07406282· Bayer· Frissítve: 2026. nov. 10.

  “The PPS data source provided insufficient level of granularity on baseline characteristics, which did not allow building comparable cohorts of matching patients. Hence, the research question(s) could not be addressed”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  High-resolution Intra-operative PSMA PET-CT in Prostate Cancer

  NCT06298838· IRCCS San Raffaele· Frissítve: 2026. nov. 6.

  “Difficulties in patient recruitment”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Prostate CA

  NCT04519879· City of Hope Medical Center· Frissítve: 2026. nov. 4.

  “05/26/2026 DSMC: Delinquent PMT reporting.”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Prostasomes as Diagnostic Tool for Prostate Cancer Detection

  NCT03694483· Hackensack Meridian Health· Frissítve: 2026. nov. 3.

  “Staffing changes, pending funding renewal”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer

  NCT05425862· Peter MacCallum Cancer Centre, Australia· Frissítve: 2026. nov. 2.

  “It was decided to stop the study due to changes in the treatment landscape.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer

  NCT07090369· Peter MacCallum Cancer Centre, Australia· Frissítve: 2026. okt. 30.

  “Funding issues”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Adaptive Radiation Therapy for Men With Intermediate- or High-Risk Prostate Cancer

  NCT07219303· Fox Chase Cancer Center· Frissítve: 2026. okt. 29.

  “Pending interim analysis”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Transperineal Micro-ultrasound for the Detection of Prostate Cancer During Biopsy

  NCT07075705· Roswell Park Cancer Institute· Frissítve: 2026. okt. 29.

  “Not planning to pursue”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  A Novel Augmented Reality System (ARssist) for the Assistant Surgeon in Robotic Assisted Surgery

  NCT04304079· Chinese University of Hong Kong· Frissítve: 2026. okt. 27.

  “No funding”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

  NCT02051218· Swiss Cancer Institute· Frissítve: 2026. okt. 23.

  “Board decision as by March 2026, the number of patients undergoing treatment decreased to around 50, from the total 1,380 patients enrolled in the trial. And due to price changes in medication”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma

  NCT07902921· National Cancer Institute (NCI)· Forrás

• Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer

  NCT07667400· National Cancer Institute (NCI)· Forrás

• Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

  NCT07140900· Amgen· Forrás

• Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

  NCT04071236· National Cancer Institute (NCI)· Forrás

• National Cancer Institute "Cancer Moonshot Biobank"

  NCT04314401· National Cancer Institute (NCI)· Forrás

• Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department

  NCT04104529· Institut du Cancer de Montpellier - Val d'Aurelle· Forrás

• Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

  NCT03866382· National Cancer Institute (NCI)· Forrás

• Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18FDCFPyL

  NCT05588128· National Cancer Institute (NCI)· Forrás

• An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC

  NCT06894511· Novartis Pharmaceuticals· Forrás

• Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue

  NCT02594202· National Cancer Institute (NCI)· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 42
• Organoids 15
• Mendelian Randomization Analysis 38
• CRISPR-Cas Systems 14
• Gene Expression Profiling 153
• Sequence Analysis, RNA 11
• Whole Genome Sequencing 9
• Exome Sequencing 4
• Proteomics 47
• Metabolomics 27
• Mass Spectrometry 16
• Flow Cytometry 58
• Immunohistochemistry 120
• Liquid Biopsy 30
• Circulating Tumor DNA 32
• Xenograft Model Antitumor Assays 287
• Positron-Emission Tomography 125
• Magnetic Resonance Imaging 464
• Machine Learning 122
• Deep Learning 101
• Cohort Studies 276
• Genome-Wide Association Study 61

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.